Therefore, we conducted a secondary analysis of data on skeletal muscle mass index (SMI), total body fat mass index (TBFMI), and the incremental area under the curves (iAUC) of plasma aGLP-1 and aGIP excursions, following mixed meal ingestion at baseline and after 24-week add-on treatment, with an αGI miglitol and/or a DPP-4 inhibitor sitagliptin in patients with type 2 diabetes (T2D) from the “Miglitol and Sitagliptin on gastric inhibitory polypeptide secretory responses in T2D patients with obesity” study (MASTER study) [19]. This evidence concerns the gene GIP and type 2 diabetes mellitus.